Matavelli LC, Huang J, Siragy HM. In vivo regulation of renal expression of (pro)renin receptor by a low-sodium diet. Am J Physiol Renal Physiol 303: F1652-F1657, 2012. First published October 17, 2012 doi:10.1152/ajprenal.00204.2012.-Effects of low salt (LS) on (pro)renin receptor (PRR) expression are not well established. We hypothesized that LS enhances renal PRR expression via the cGMPprotein kinase G (PKG) signaling pathway. Sprague-Dawley rats were fed a normal-salt (NS) or LS diet associated with intrarenal cortical administration of vehicle (V), the nitric oxide (NO) synthase inhibitor nitro-L-arginine methyl ester (L-NAME), the NO donor S-nitroso-Nacetyl-DL-penicillamine (SNAP), the cGMP analog 8-bromoguanosine (8-Br)-cGMP, the guanylyl cyclase inhibitor 1H-[1, 2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), or a PKG inhibitor (PKGi) for 6 days via osmotic minipump. We evaluated the effects of each treatment on renal interstitial fluid (RIF) levels of nitrate/nitrite and cGMP and renal PRR expression. There were no significant changes in blood pressure with any of the treatments. Urinary sodium excretion was significantly lower in rats given a LS diet. Compared with NS ϩ V, RIF nitrate/nitrite and cGMP levels increased in LS ϩ V rats. In NS groups, RIF nitrate/nitrite and cGMP levels did not change with L-NAME, ODQ, or PKGi and increased in response to SNAP. 8-BrcGMP increased RIF cGMP but not RIF nitrate/nitrite. In LS groups, RIF nitrate/nitrite decreased with L-NAME and did not change with ODQ or PKGi whereas RIF cGMP decreased with L-NAME, ODQ, and PKGi. PRR mRNA and protein increased in LS ϩ V. In NS rats, PRR mRNA and protein increased in response to 8-Br-GMP and were not affected by any of other treatments. In LS rats, PRR mRNA and protein decreased significantly in response to L-NAME, ODQ, and PKGi. We conclude that LS intake enhances renal expression of PRR via cGMP-PKG signaling pathway. renin; salt intake; kidney; nitric oxide UNDER PHYSIOLOGIC CONDITIONS, sodium depletion upregulates most components of the renin-angiotensin system (RAS; Ref. 9), including the (pro)renin receptor (PRR; Ref. 11). However, the physiologic regulations of PRR in the kidney have not been established yet. PRR is localized in diverse kidney structures including glomerular mesangial cells and podocytes, renal vasculature, proximal and distal nephron, and collecting duct cells (2, 8, 12, 21) . PRR binds both renin and its precursor prorenin leading to generation of angiotensin (ANG) II and activation of different intracellular signaling cascades, independent of ANG II (2, 12, 21). However, recent studies suggested that PRR requires agonist concentrations of renin/prorenin that are far above the levels in wild normal animals and that this receptor may function independent of renin/prorenin (2).
UNDER PHYSIOLOGIC CONDITIONS, sodium depletion upregulates most components of the renin-angiotensin system (RAS; Ref. 9) , including the (pro)renin receptor (PRR; Ref. 11) . However, the physiologic regulations of PRR in the kidney have not been established yet. PRR is localized in diverse kidney structures including glomerular mesangial cells and podocytes, renal vasculature, proximal and distal nephron, and collecting duct cells (2, 8, 12, 21) . PRR binds both renin and its precursor prorenin leading to generation of angiotensin (ANG) II and activation of different intracellular signaling cascades, independent of ANG II (2, 12, 21) . However, recent studies suggested that PRR requires agonist concentrations of renin/prorenin that are far above the levels in wild normal animals and that this receptor may function independent of renin/prorenin (2) .
Similarly, low-salt (LS) intake enhances renal interstitial concentration of nitric oxide (NO) and its second messenger cyclic guanosine 3=,5=-monophosphate (cGMP; Refs. 1, 25) , leading to stimulation of cGMP-dependent protein kinase G (PKG) signaling pathway (7) . cGMP-PKG signaling is an important component of many intracellular signal processes that contribute to gene expression through transcriptional and posttranscriptional mechanisms (7, 23) . In the kidney, the cGMP-PKG signaling pathway has multiple physiologic roles, including the modulation of renal hemodynamic and excretory functions (14, 15, 17) .
The contribution of the cGMP-PKG pathway to the expression of PRR represents a novel aspect on how this receptor is regulated in the kidney. It is possible that in the kidney stimulation of PRR expression could be a part of increased RAS activity to minimize inappropriate water and salt excretion and blood pressure reduction during LS intake. In the present study, we tested the hypothesis that in vivo LS intake enhances renal expression of PRR via cGMP-PKG signaling pathway.
MATERIALS AND METHODS
Animal preparation. The University of Virginia Animal Care and Use Committee approved all study protocols. Experiments were conducted in 4-wk-old male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA). Animals were allowed 1 wk to adjust to our animal care facility. Rats were provided tap water ad libitum and randomly fed normal salt (NS; 0.50% NaCl) or LS (0.05% NaCl; Harlan-Teklad, Madison, WI) diets. Rats were allocated into 10 groups according to salt intake and provided treatment. NS groups received vehicle (V; n ϭ 10), the cGMP analog 8-bromoguanosine 3=,5=-cyclic monophosphate (8-Br-cGMP; n ϭ 9), the NO synthase enzyme inhibitor nitro-L-arginine methyl ester (L-NAME; n ϭ 10), the NO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP; n ϭ 9), the soluble guanylyl cyclase inhibitor 1H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ; n ϭ 10), or the PKG inhibitor Rp-8-pCPTcGMPS (PKGi; n ϭ 9). LS groups received vehicle (n ϭ 9), L-NAME (n ϭ 9), ODQ (n ϭ 10), or PKGi (n ϭ 9). Vehicle (V, deionized distilled water), L-NAME (100 ng·kg·min), SNAP (0.12 mol·l
) treatments were started at the same time and infused directly into the left renal cortex interstitium using osmotic minipumps (model 2001; Alzet, Cupertino, CA) for 6 days.
Surgical procedures. For renal interstitial infusion catheters implantation, rats were anesthetized with the combination of ketamine (80 mg/kg ip) and xylazine (8 mg/kg ip) and placed on a heating pad throughout the surgery period. With the use of a sterile technique, a midline laparotomy was performed and an osmotic minipump, connected to a polyethylene tubing (PE)-10 (Beckton Dickinson, Sparks, MD), was implanted intraperitoneally. The left kidney was exposed, and the tip of the PE-10 catheter was inserted under the left kidney capsule and glued in place with Vetbond (3M Animal Care Products, Saint Paul, MN) to prevent dislodging.
Systolic blood pressure and 24-h urinary sodium excretion monitoring. Systolic blood pressure (SBP) and 24-h urinary sodium excretion (U NaV) were obtained at baseline and at the end of study. SBP was assessed in nonanesthetized rats using a tail-cuff noninvasive multichannel blood pressure system (IITC Life Sciences, Woodland Hills, CA). To confirm LS intake, rats were placed in individual metabolic cages for a period of 24-h. The volumes of collected urine were determined gravimetrically, and urine aliquots were stored at Ϫ80°C until assayed. The urinary sodium concentration of each sample was measured using a flame photometer IL 943 (Instrumentation Laboratory, Bedford, MA).
In vivo renal interstitial fluid collections. To determine the renal interstitial fluid (RIF) levels of NO and cGMP, we constructed a microdialysis probe as previously described (26, 27) . In this technique, substances with a molecular mass Ͼ40,000 Da cannot cross the dialysis membrane but allowing the free passage of smaller molecules. At the end of the 6-day period of study, RIF collections from left kidney were performed in each animal while it was under sodium pentobarbital anesthesia (50 mg/kg ip; Sigma-Aldrich, St. Louis, MO). In this procedure, a dialysis catheter was placed in the left kidney cortex through a midline laparotomy. In brief, a 30-gauge needle was tunneled ϳ1-2 mm from the outer renal surface for ϳ0.5 cm before it exited by penetrating the capsule again. The tip of the needle was then inserted into one end of the dialysis probe, and the needle was pulled together with the dialysis tube until the dialysis fiber was situated into the renal cortex. To prevent dislodging, the dialysis probe was glued to the surface of the kidney using Vetbond. Thereafter, the inflow tube of the dialysis probe was connected to a gas-tight syringe filled with saline and perfused at a rate of 3 l/min using an infusion pump. After a 60-min stabilization period following completion of surgical procedures, the effluent was collected from the outflow tube in nonheparinized plastic tubes over ice through five periods of 60-min each with an amount of ϳ180 l in each sample. At the end of each experiment, animals were euthanized and kidneys were harvested. For histological analyses, a part of each kidney was immersed in Bouin's fixative solution (Sigma). The remaining kidney tissues were immediately frozen in liquid nitrogen and stored at Ϫ80°C for mRNA and protein analysis.
RIF storage and assays. The RIF collections were immediately stored at Ϫ80°C until assayed. RIF nitrate/nitrite (NOx) recovery levels were measured using a fluorometric assay kit (CaymanChemical, Ann Harbor, MI) and presented as micromoles per minute. NOx are the main metabolite products of NO in vivo, and they are considered the best index of total NO production. RIF cGMP recovery levels were measured using a cGMP ELISA immunoassay kit (Cayman) and expressed as fentomoles per minute.
Determination of mRNA expression. Quantitative real-time RT-PCR was used to determine changes in renal expression of PRR mRNA. The RNA (n ϭ 5, each group) was extracted using Trizol (Invitrogen, Carlsbad, CA). Reverse transcription of the RNA was performed by the first-strand cDNA synthesis kit (Bio-Rad, Hercules, CA). The PCR was analyzed using SYBR Green Supermix (Bio-Rad). Primer sequences were as follows: PRR, forward sequence 5=-GAG-GCAGTGACCCTCAACAT-3= and reverse sequence 5=-CCCTCCT-CACACAACAAGGT-3=; and for 18S rRNA, forward sequence 5=-CGAAAGCATTTGCCAAGAAT-3= and reverse sequence 5=-AGTCGGCATCGTTTATGGTC-3=. RT-PCR was performed using iCycler (Bio-Rad), and threshold cycle number was determined using iCycler software version 3.0 (Bio-Rad). Reactions were performed in triplicate, and threshold cycle numbers were averaged. The mRNA results for specific target genes were calculated with normalization to 18S rRNA.
Western blot analysis. Antibody to PRR (anti-ATP6IP2/ab40790; Abcam, Cambridge, MA) was used in the Western blot. Signal detection was carried out by using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Rockford, IL). The blots were treated using Restore Western Blot Stripping Buffer (Thermo Fisher) according to the manufacturer's recommendation and followed by reprobing with a monoclonal antibody against GAPDH (Sigma). Densitometry evaluation of the bands was done using ImageMaster TotalLab software version 2.0 (Amersham Pharmacia Biotech, Piscataway, NJ). The bands densities of target proteins were normalized to the corresponding density of GAPDH . The arbitrary unit of band densities was represented as the expression level.
Renal PRR immunostaining. The kidney tissue blocks were embedded in paraffin and cut into 3-m slices. After being deparaffinized using xylene and ethanol dilutions and rehydration, kidney sections were incubated overnight at 4°C with primary antibody directed against rabbit PRR monoclonal antibody (1:100 dilution; anti-ATP6IP2/ab40790; Abcam). On the next day, sections were incubated for 1h with secondary antibody at room temperature. A negative control (IgG) was included by omitting the primary antibody. The immunostaining images were captured by light microscopy using a Qimaging Micropublisher 5.0 RTV camera coupled to a Zeiss Axiophot microscopy (Carl Zeiss, Jena, Germany). Immunostaining quantification was performed (16) utilizing ImageJ software (National Institutes of Health, Bethesda, MD).
Statistical analysis. Comparisons among different treatment groups were assessed by ANOVA followed by a Tukey test for post hoc comparisons. Data are expressed as mean Ϯ SE. P Ͻ 0.05 is considered statistically significant.
RESULTS
SBP and 24-h U Na V. At baseline, there were no significant differences in mean SBP between all rat groups. At the end of study, compared with NS ϩ V group mean SBP was significantly lower in LS ϩ V rats (106 Ϯ 1 and 102 Ϯ 1 mmHg, respectively; P Ͻ 0.02). SBP was not significantly affected by any of the administered treatments in both the NS and LS diet groups. U Na V at the end of study was significantly lower in LS ϩ V than NS ϩ V (6.4 Ϯ 0.7 vs. 708 Ϯ 49 mol/day, respectively, P Ͻ 0.0001) rats. Compared with NS ϩ V, U Na V significantly increased by treatments with NS ϩ cGMP (873 Ϯ 45 mol/day; P Ͻ 0.04) and NS ϩ SNAP (868 Ϯ 27 mol/day; P Ͻ 0.03) and were not affected by NS ϩ L-NAME (663 Ϯ 16 mol/day), NS ϩ ODQ (644 Ϯ 35 mol/day), and NS ϩ PKGi (672 Ϯ 25 mol/day). Compared with LS ϩ V, U Na V was significantly reduced in LS rats treated with L-NAME (4.3 Ϯ 0.6 mol/day; P Ͻ 0.03), ODQ (3.7 Ϯ 0.8 mol/day; P Ͻ 0.02) and PKGi (2.1 Ϯ 0.4 mol/day; P Ͻ 0.01; Fig. 1) .
RIF NOx and cGMP in treated kidneys in response to manipulations of NO-cGMP-PKG cascade. RIF NOx ( Fig. 2A) and RIF cGMP (Fig. 2B ) recovery levels increased significantly by 51% (P Ͻ 0.001) and 53% (P Ͻ 0.03), respectively, in LS ϩ V compared with NS ϩ V rats. In rats given the NS diet, RIF NOx levels significantly increased in response to SNAP treatment (42%; P Ͻ 0.01) and did not significantly change in rats treated with cGMP, L-NAME, ODQ, or PKGi. In LS diet rats, RIF NOx significantly decreased in response to L-NAME (Ϫ45%; P Ͻ 0.001) and did not change in response to ODQ or PKGi. RIF cGMP levels, in rats given NS diet, significantly increased in response to cGMP (95%; P Ͻ 0.03) and SNAP (64%; P Ͻ 0.03) and did not change with L-NAME, ODQ, or PKGi treatments. In contrast, in LS diet rats, RIF cGMP levels were significantly reduced with L-NAME (Ϫ29%; P Ͻ 0.02), ODQ (Ϫ38%; P Ͻ 0.02), or PKGi (Ϫ48%; P Ͻ 0.01) treatments.
Expression of PRR in treated kidneys. Compared with NS ϩ V, renal PRR mRNA (Fig. 3A) and protein (Fig. 3B) expressions in left kidneys were significantly increased (186 and 240%, respectively; P Ͻ 0.02) in LS ϩ V rats. In NS diet rats, PRR mRNA and protein levels increased with cGMP (60 and 122%; P Ͻ 0.02) but did not change with any other treatment. In rats given the LS diet, renal expression of PRR mRNA (Fig.  3A) and protein (Fig. 3B) were significantly reduced in kidneys treated with L-NAME (Ϫ39 and Ϫ61%, respectively; P Ͻ 0.04), ODQ (Ϫ64 and Ϫ62%; P Ͻ 0.01), or PKGi (Ϫ50 and Ϫ56%; P Ͻ 0.02).
Immunohistochemistry for PRR in treated kidneys. Compared with animals given NS diet (Fig. 4B) , rats given the LS diet (Fig.  4H ) had increased PRR immunostaining in glomeruli and tubules.
The comparison within NS diet groups showed that PRR immunostaining increased in kidney sections of cGMP (Fig. 4C )-treated rats and was not affected by treatments with L-NAME (Fig. 4D) , SNAP (Fig. 4E) , ODQ (Fig. 4F ), or PKGi (Fig. 4G) . In LS diet rats, treatments with L-NAME (Fig. 4I) , ODQ (Fig. 4J ), or PKGi (Fig. 4K) reduced renal PRR immunostaining.
DISCUSSION
In the kidney, LS intake reduces sodium chloride delivery to macula densa cells in the distal nephron triggering the secretion of renin by the juxtaglomerular apparatus and increasing the renal expression of ANG type 1 and type 2 receptors (5, 22) . However, the effects of LS on renal PRR expression are not well elucidated. Our experiments were performed in young rats that usually express more components of the RAS than older rats (13, 22) . The results of the present study demonstrated that in young rats LS intake increases the renal expression of PRR. We also demonstrated that pharmacologic interventions affecting renal cGMP-PKG signaling pathway influenced the renal expression of PRR and were enhanced by LS intake.
While extensive studies of PRR are ongoing, the factors influencing this receptor expression and its role in physiology and pathophysiology are still evolving. PRR consists of 350 amino acids protein with a single transmembrane domain that binds both prorenin and renin. The involvement of PRR in intracellular signaling processes was recently investigated in our laboratory. We demonstrated that in the presence of high glucose levels PRR is involved in renal production of inflammatory cytokines, transforming growth factor-␤1, and connective tissue growth factor (10, 18) .
In current experiments, LS intake was confirmed by a significant reduction in U Na V. Under LS intake conditions, treatments with L-NAME, ODQ, or PKGi further reduced U Na V. In contrast, in animals given the NS diet, U Na V was not influenced by treatments with L-NAME, ODQ, or PKGi while it was increased by cGMP and SNAP. These results are consistent with previous studies demonstrating the influence of NO and cGMP in mediating natriuresis (14, 15, 17, 19) . However, although treatments were administered into left kidneys only, urine was collected from both kidneys. Thus the observed changes in U Na V may not be limited to changes in renal function of the treated kidneys.
We also demonstrated that the observed changes in U Na V were directly related to variations in renal levels of NO or its second messenger cGMP. Under NS intake conditions, renal interstitial levels of NO and cGMP were respectively enhanced in response to exogenous administration of the NO donor SNAP and cGMP analog 8-Br-cGMP. In contrast, renal levels of NO and cGMP were not affected by treatments with the NO synthase inhibitor, the irreversible inhibitor of guanylyl cyclase, or PKGi. In rats given a LS diet, our results are consistent with the earlier findings that a LS diet increases renal production of NO and cGMP (1, 25) . In these groups of rats, treatment with L-NAME significantly reduced renal interstitial levels of both NO and cGMP while treatments with ODQ or PKGi did not affect renal levels of NO but reduced renal cGMP. These findings confirm that we were able to inhibit the increased renal production of NO and cGMP induced by LS intake. ODQ and PKGi treatments were not expected to affect NO production since they function distally to NO synthase. ODQ treatment reduced renal cGMP generation; however, our finding of reduced renal production of cGMP with PKGi treatment was unanticipated and could not be explained based on current study design. A previous study did not find changes in renal cGMP levels after acute infusion of PKGi, although its chronic effects were not investigated (14) . The PKGi Rp-8-pCPT-cGMPS, used in our current experiments, is highly specific for PKG and a competitive inhibitor of all PKG isozymes (24) . It is possible that differences in specificity, efficacy, and permeability of different PKG inhibitors may influence cGMP production (4, 28) .
The observed increased renal PRR expression in LS diet animals parallels the changes in NO-cGMP activity associated with LS intake. The increase in RAS activity and PRR expression on LS intake is not unique. Low salt intake increases RAS activity and angiotensin II type 1 receptor expression and represents a physiologic protective mechanism to prevent inappropriate water and salt excretion and blood pressure reduction during LS. The observed changes in PRR expression during LS may suggest a possible role for this receptor in regulating renal function during LS intake. However, our study was not designed to investigate if increased renal PRR expression with a short-term LS diet would cause any change to kidney function. It is also unknown whether chronic LS diet condition would enhance renal PRR activity or if this receptor plays a role in modifying renal function under this prolonged stressful situation. Future studies should aim to explore this issue. Under NS intake condition, 8-Br-cGMP treatment increased renal levels of cGMP and increased renal PRR mRNA and protein expressions. In addition, the observed changes in renal PRR expression during manipulations of the cGMP and PKG under LS intake condition confirm the involvement of these elements in the regulation of this receptor expression. Previous studies demonstrated that the NO-cGMP-PKG signaling pathway promotes a variety of phosphorylation reactions that directly affect renal hemodynamic and excretory functions (14, 15) . In addition, cGMP is a key regulator of cell proliferation, differentiation, and apoptosis (23) . Similarly, PKG influences gene expression in a number of cell types, including vascular smooth muscle, macrophages, osteoblasts, and neuronal cells (3, 20, 29) . Our results suggest that PRR is a possible mediator of the effects of increased renal activity of cGMP-PKG pathway induced by LS intake. Recently, we demonstrated in vitro in both proximal tubule cells and inner medullary collecting duct cells some of the molecular mechanisms regulating PRR gene activity under the LS condition (11) . In this previous study, the cGMP-PKG pathway mediated the activation of cAMP response element binding protein 1, nuclear factor-B p65, and c-Jun, and these transcription factors enhanced transcription regulation of PRR, which in turn was amplified by LS (11) . Another explanation for the influence of NO-cGMP-PKG could be related to the influence of this pathway on renin production (27) . Inhibition of NO-cGMP was demonstrated to reduce renin (27) , which in turn could inhibit the negative feedback of renin on PRR (6) .
We conclude that LS intake increases the renal expression of PRR in vivo via enhanced cGMP-PKG signaling pathway. Future studies are needed to evaluate the role of chronic LS intake on PRR expression and activity and the role of this receptor in renal physiology and pathology.
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